Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases
VANCOUVER, British Columbia and CAMBRIDGE, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.(NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced its alliance with the National Organization for Rare Disorders (NORD), Rare Diseases Europe (EURORDIS), Canadian Organization of Rare Disorders (CORD), and The Global Genes Project, among others, in observance of the annual Rare Disease Day.
Interim Chief Executive Officer Ben Harshbarger commented, “Today we join with others in the community to raise awareness of rare diseases. The theme of this year’s Rare Disease Day is Bridging Health and Social Care, highlighting the existing gaps between medical, social and support services that present challenges for families living with a rare disease. We are honored to have the opportunity to contribute by supporting our patients and continuing to deliver much needed therapies to those in need.”
In the United States, a rare disease is defined as one that affects fewer than 200,000 persons. According to the National Institutes of Health (NIH), there are nearly 7,000 rare diseases affecting nearly 30 million Americans. Rare Disease Day was established by EURORDIS and was first observed in Europe in 2008. In 2009, EURORDIS partnered with NORD for this initiative in the U.S. For more information about Rare Disease Day, visit www.rarediseaseday.us or www.rarediseaseday.org.
About Novelion Therapeutics
Novelion, through its subsidiary Aegerion Pharmaceuticals, is a global biopharmaceutical company dedicated to developing and commercializing therapies that deliver new standards of care for people living with rare and underserved metabolic diseases. Our goal is to develop and bring to market transformational therapies that have the potential to significantly change the treatment paradigm for patients affected by a variety of rare and metabolic diseases, including diseases associated with low leptin. With a global footprint and an established commercial portfolio, including MYALEPT® (metreleptin) and JUXTAPID® (lomitapide), our business is supported by differentiated treatments that treat severe and rare diseases.
Amanda Murphy, Director, Investor Relations & Corporate Communications
Source: Novelion Therapeutics, Inc.